Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY2409021 on Blood Pressure and Pulse Rate in Participants With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have type 2 diabetes mellitus (according to the World Health Organization diagnostic criteria) and use diet and exercise alone or in combination with a stable dose of metformin ( \>/=1000 mg/day \[or \<1000 mg, if documented intolerance to 1000 mg or higher dosages\] immediate-release metformin or extended-release metformin for at least 2 months before screening).~* Have glycated hemoglobin (HbA1c) values \>/=6.5% and \</=8.5%, as determined by the central laboratory at screening.~* Have mean blood pressures \>90/60 millimeters of mercury (mm Hg) and \<140/90 mm Hg at screening.~* If being treated for hypertension, are taking 3 or fewer antihypertensive medications and have been taking stable doses of the same medications for at least 1 month before screening.~* Stable body weights (±5%) for \>/=3 months before screening.~* Body mass indexes \>/=20 kilograms/meters squared (kg/m²) and \<40 kg/m².~* In the investigator's opinion, are well motivated, capable, and willing to:~  * Reliably administer the oral study drug once daily;~ * Maintain a study diary;~ * Perform self-monitored blood glucose testing; and~ * Wear an ambulatory blood pressure monitoring device for at least 24 hours (on multiple occasions).~* Are women not of child-bearing potential due to:~  * Surgical sterilization, hysterectomy, or bilateral oophorectomy (at least 6 weeks postsurgery) or tubal ligation (confirmed by medical history); or~ * Menopause. Women with an intact uterus are deemed menopausal if they have a cessation of menses for at least 1 year with follicle stimulating hormone \>40 milli-international units per milliliter (mIU/mL), are not taking hormones or oral contraceptives within 1 year, and are otherwise healthy.~* Males who are sexually active and/or have partners of child-bearing age must use reliable methods of birth control during the study and until 3 months after the last doses of study medication. These requirements do not apply if a participant or his partner has been surgically sterilized or is not between menarche and 1 year postmenopausal.~Exclusion Criteria:~* Have severe gastrointestinal disease that may significantly affect gastric emptying or motility.~* Previous histories or active diagnoses of pancreatitis.~* Acute or chronic hepatitis, signs or symptoms of any other liver disease, or alanine aminotransferase (ALT) level greater than 2.5 times the upper limit of normal (ULN).~* Elevated total bilirubin (greater than 2 times ULN), clinically suspicious signs or symptoms of cirrhosis or history of cirrhosis.~* Mean resting pulse rate (PR) less than 60 beats per minute (bpm) or greater than 100 bpm.~* Current diagnosis or personal history of neuroendocrine tumors, family history of any type of multiple endocrine neoplasia, or Von Hippel-Lindau disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Single daily dose of placebo matching LY2409021 administered orally in 1 of 2 treatment periods.
- LY2409021 (Type: EXPERIMENTAL): Single daily dose of 20 milligrams (mg) LY2409021 administered orally in 1 of 2 treatment periods.

Based on this trial design, predict the completion outcome and termination type (if applicable).